Last updated: September 29, 2026
Epivir is the branded lamivudine product marketed by ViiV Healthcare for HIV-1 infection and, in a separate formulation, by GlaxoSmithKline for chronic hepatitis B under the name Epivir-HBV. Its commercial trajectory is mature and declining. Core composition-of-matter protection expired years ago, generic lamivudine is widely available, and current value depends on residual brand prescriptions, combination-product positioning, institutional supply, and manufacturing scale rather than exclusivity.
Epivir Market Dynamics, Patent Expiration, Generic Competition, and Financial Trajectory
What is Epivir and who markets it?
Epivir contains lamivudine, a nucleoside reverse transcriptase inhibitor, or NRTI. The drug inhibits HIV reverse transcriptase and hepatitis B virus DNA polymerase after intracellular conversion to its active triphosphate form.
| Product |
Active ingredient |
Primary indication |
Brand owner or marketer |
Regulatory status |
| Epivir tablets and oral solution |
Lamivudine |
HIV-1 infection, with other antiretroviral agents |
ViiV Healthcare |
FDA-approved |
| Epivir-HBV tablets |
Lamivudine |
Chronic hepatitis B |
GlaxoSmithKline |
FDA-approved |
| Generic lamivudine |
Lamivudine |
HIV-1 infection and other approved uses |
Multiple manufacturers |
FDA-approved |
ViiV Healthcare is majority owned by GSK, with Pfizer and Shionogi as minority shareholders. GSK transferred its HIV business into ViiV in 2009, creating the commercial structure that now manages Epivir in HIV markets (GSK, 2009).
Epivir is a legacy small-molecule product. It is not a biologic and does not create biosimilar exposure. Competitive pressure comes from generic lamivudine and newer HIV treatment regimens.
When did Epivir lose market exclusivity?
Epivir lost meaningful U.S. market exclusivity after expiration of the principal lamivudine patent estate and regulatory exclusivity periods. Generic entry occurred more than a decade ago.
The core U.S. patent commonly associated with lamivudine was U.S. Patent No. 5,047,407, which covered lamivudine and related nucleoside analog chemistry. The patent was assigned to BioChem Pharma, later acquired by Shire, and was listed with an expiration date in the late 2000s. Pediatric exclusivity and regulatory extensions affected the practical timing of generic entry but did not preserve long-term brand exclusivity.
The original U.S. patent position has no current blocking effect on generic lamivudine. Any remaining listed patents would be assessed through the FDA Orange Book and product-specific patent certifications, but the commercial market is already genericized.
Epivir exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| U.S. approval of Epivir for HIV |
1995 |
Established lamivudine as an NRTI |
| U.S. approval of Epivir-HBV |
1998 |
Expanded use into chronic hepatitis B |
| Core lamivudine patent expiry |
Late 2000s |
Opened market to generic competition |
| Generic lamivudine availability |
2010s |
Accelerated price and volume erosion |
| Current market |
2020s |
Mature, low-growth, generic-dominated market |
The precise launch date for each generic manufacturer varied by product, dosage form, and settlement or regulatory timing. The central conclusion is unchanged: Epivir no longer has a commercially meaningful period of patent exclusivity.
What patents protect Epivir today?
No active composition-of-matter patent provides a durable U.S. barrier to generic lamivudine tablets or oral solution.
Potentially relevant intellectual-property categories include:
- Lamivudine composition patents. These patents drove the original protection period but have expired.
- Polymorph or solid-state patents. These can matter if a manufacturer claims a specific crystal form, but they do not generally block ordinary generic lamivudine where the approved reference product can be reproduced without the protected form.
- Formulation patents. Controlled-release, taste-masked, pediatric, or combination formulations can create narrower protection. Epivir's conventional immediate-release tablets and oral solution have limited practical protection from such secondary patents.
- Method-of-use patents. Potential uses in HIV or hepatitis B may have been listed historically, but treatment-method patents do not recreate broad product exclusivity once generic manufacturers can market the active ingredient for approved uses.
- Manufacturing patents. Process patents may affect cost and supply, but they are usually difficult to enforce against a finished-product manufacturer without evidence that the accused process is used in the relevant jurisdiction.
What formulations are protected by Epivir patents?
The commercially important Epivir formulations are immediate-release tablets and oral solution. Their principal competitive characteristic is dosage-form availability, not patent protection.
The tablet strengths historically marketed for HIV include 150 mg and 300 mg. Pediatric and liquid formulations support use in children and patients unable to swallow tablets, but the existence of an oral solution does not prevent generic manufacturers from filing abbreviated new drug applications for equivalent liquid products.
Epivir-HBV was marketed as a 100 mg tablet. Its indication-specific branding separated hepatitis B positioning from the higher-dose HIV product but did not create a durable barrier against generic lamivudine.
What is the FDA regulatory and Orange Book status of Epivir?
Epivir is an FDA-approved small-molecule prescription drug. Its approved HIV indication requires use with other antiretroviral agents. Epivir-HBV is a separate product with a chronic hepatitis B indication.
The FDA Orange Book identifies approved drug products, dosage forms, therapeutic equivalence information, and patent-related listings. Generic lamivudine products may be designated therapeutically equivalent to the relevant reference products where FDA requirements are met.
| Regulatory issue |
Epivir assessment |
| FDA pathway |
Original new drug application |
| Generic pathway |
Abbreviated new drug application under section 505(j) |
| Orange Book relevance |
Product-specific patent and therapeutic-equivalence listings |
| Reference-product status |
Legacy reference product |
| Pediatric exclusivity |
Historical, not commercially operative today |
| Orphan-drug status |
Not a material exclusivity driver |
| Biosimilar pathway |
Not applicable |
The main current regulatory risk is not loss of approval. It is continued substitution by lower-priced generic products and the gradual reduction of brand prescribing.
Which companies are challenging Epivir with generics?
Generic lamivudine has been supplied by multiple manufacturers and distributors, including large generic companies such as Teva, Mylan/Viatris, Cipla, Aurobindo, and other FDA-approved suppliers, depending on dosage form and market period.
Competition occurs at several levels:
- Single-agent lamivudine: Generic tablets and oral solution directly substitute for Epivir.
- Fixed-dose combinations: Lamivudine is incorporated into products such as Combivir, Triumeq, and other antiretroviral combinations. These products compete for clinical use but are not always direct substitutes for Epivir.
- Alternative NRTIs: Tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, and abacavir have displaced lamivudine in many modern regimens.
- Modern complete regimens: Integrase inhibitor-based combinations have reduced the role of older NRTI-based treatment structures.
There is no meaningful biosimilar threat because lamivudine is a chemically synthesized small molecule. The relevant market challenge is generic substitution.
How strong is the Epivir patent estate?
The current patent estate is weak as a commercial defense.
| Patent-strength factor |
Assessment |
| Core composition patent |
Expired |
| Broad formulation protection |
Limited practical relevance |
| Method-of-use protection |
Narrow and generally expired or nonblocking |
| Manufacturing barriers |
Possible at process level, but not a broad market barrier |
| Orange Book leverage |
Low |
| Generic substitution risk |
High |
| Litigation leverage |
Low for the legacy product |
Epivir's residual commercial value is based on brand recognition, procurement relationships, regulatory history, and supply reliability. Those factors can support price premiums in certain channels but cannot offset broad generic availability.
What patent litigation and Paragraph IV challenges affected Epivir?
The major litigation risk for lamivudine occurred before and around generic entry, when generic applicants could file Paragraph IV certifications asserting that listed patents were invalid, unenforceable, or not infringed.
A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act and potentially create a 30-month stay of FDA approval. That mechanism was commercially relevant during the original generic challenge period. It is not a material current barrier because the core patent estate has expired and lamivudine has long been sold generically.
No active litigation is broadly recognized as capable of restoring Epivir exclusivity in the U.S. market. Any individual patent dispute would likely concern a specific manufacturer, formulation, process, or jurisdiction rather than the entire lamivudine market.
What settlement agreements affected generic launch?
Generic settlements, if used during the historic patent challenge period, would have had value only until the relevant patent expiry or agreed launch date. They have no current ability to prevent ordinary generic supply after expiration of the principal patent rights.
Because Epivir is a mature product, settlement economics now have little impact on market entry. Commercial outcomes are determined by FDA approvals, manufacturing capacity, wholesaler contracts, tender procurement, and reimbursement.
What is Epivir's financial trajectory?
GSK and ViiV generally report HIV portfolio performance at a broader franchise level rather than providing a current standalone Epivir revenue line. As a result, Epivir's precise annual revenue and margin cannot be reliably derived from public company reporting.
The financial trajectory is nevertheless clear:
- 1990s to early 2000s: rapid growth. Epivir became a foundational NRTI and generated value through branded monotherapy components and combination products.
- Mid-2000s: portfolio integration. The drug increasingly contributed to combination regimens such as Combivir and Epzicom rather than functioning as a standalone growth product.
- 2010s: generic erosion. Generic lamivudine and newer antiretrovirals reduced standalone Epivir volume and pricing.
- 2020s: residual revenue. Remaining sales are concentrated in legacy prescribing, pediatric use, selected international markets, institutional procurement, and patients for whom lamivudine remains clinically or economically suitable.
Revenue exposure and margin profile
| Financial variable |
Current direction |
| Branded unit volume |
Declining or stable at low levels |
| Net price |
Under pressure from generic substitution |
| Gross margin |
Lower than during exclusivity |
| Commercial spending |
Reduced relative to strategic HIV products |
| Manufacturing economics |
Favorable at scale but exposed to low-volume inefficiency |
| Portfolio importance |
Low compared with newer ViiV products |
| Standalone growth potential |
Minimal |
Epivir should not be valued as a growth asset. It is a mature cash-flow product with limited pricing power and high substitution risk.
How does Epivir compare with competing HIV drugs?
| Drug or product |
Main competitive role |
Exclusivity profile |
Current commercial position |
| Epivir, lamivudine |
Legacy NRTI |
Expired |
Generic-dominated |
| Emtriva, emtricitabine |
Alternative NRTI |
Mature and largely genericized |
Used mainly in combinations |
| Viread, tenofovir DF |
NRTI with HIV and HBV use |
Expired in major markets |
Generic and widely used |
| Vemlidy, tenofovir alafenamide |
Newer HBV/NRTI product |
Later-generation patents |
Stronger residual branded protection |
| Triumeq |
Dolutegravir/abacavir/lamivudine combination |
Combination-product patent estate |
More commercially relevant than standalone Epivir |
| Dovato |
Dolutegravir/lamivudine combination |
Later-generation combination protection |
Strategic ViiV product |
| Biktarvy |
Bictegravir/emtricitabine/tenofovir alafenamide |
Later-generation branded regimen |
Major competitor in HIV treatment |
Lamivudine remains clinically useful because it is inexpensive, familiar, orally available, and compatible with many regimens. It has been displaced commercially by newer complete regimens rather than eliminated clinically.
What generic launch scenarios exist for Epivir?
The principal generic launch scenarios are already realized:
- Broad substitution: Pharmacies dispense generic lamivudine in place of Epivir where state substitution rules and payer formularies permit.
- Tender-driven pricing: Hospitals, public programs, and international procurement agencies select the lowest compliant supplier.
- Shortage-driven volatility: A manufacturing disruption at one or more suppliers can temporarily increase demand for branded or alternative generic sources.
- Specialty formulation retention: Pediatric oral solution demand can support a limited premium where fewer suppliers participate.
- Combination-product migration: Prescribers use newer fixed-dose combinations rather than prescribing standalone Epivir.
A branded relaunch with a materially higher price is unlikely to succeed without a differentiated delivery system, new indication, or supply-reliability advantage.
What geographic markets still matter for Epivir?
The U.S. market has the highest generic substitution pressure. Epivir can retain greater brand presence in markets where:
- generic registration is slower;
- public procurement favors established suppliers;
- physicians continue using legacy regimens;
- local supply is inconsistent;
- reimbursement rules do not automatically substitute generic products.
International revenue is difficult to attribute because GSK and ViiV report regional or franchise-level performance, and local distributors may sell lamivudine under multiple brand names. In lower-income markets, generic lamivudine is often a key component of public HIV programs, making branded Epivir commercially less important but preserving overall demand for the active ingredient.
What manufacturing and intellectual-property barriers remain?
The principal manufacturing issues are cost, quality, and supply continuity rather than patent exclusion.
Manufacturers must maintain validated synthesis, impurity control, bioequivalence, stability, and regulatory compliance. Lamivudine has a stereochemical requirement, so control of the correct enantiomer is important. These requirements create technical execution risk but do not prevent capable generic manufacturers from competing.
Supply risk can arise from:
- concentration of active pharmaceutical ingredient production;
- limited suppliers for pediatric liquid formulations;
- low margins that cause manufacturers to exit;
- regulatory inspections or remediation;
- procurement contracts that favor a small number of suppliers.
Those factors can affect short-term availability and pricing. They do not materially strengthen Epivir's long-term patent position.
What licensing deals affect Epivir?
The most important strategic transaction was GSK's creation of ViiV Healthcare in 2009 with Pfizer. Shionogi later joined as a shareholder. The transaction placed GSK's HIV portfolio, including Epivir, within a dedicated HIV company (GSK, 2009; ViiV Healthcare, n.d.).
ViiV has also used licensing and access agreements across HIV products and markets, but those arrangements are more relevant to newer antiretrovirals and public-health access than to standalone Epivir exclusivity. Generic and voluntary-licensing arrangements can expand access to lamivudine without preserving brand economics.
Key Takeaways
- Epivir is branded lamivudine for HIV; Epivir-HBV is the hepatitis B version.
- The core lamivudine patent estate expired years ago.
- Generic competition is the dominant market force in the U.S. and other developed markets.
- Epivir has no biosimilar risk because it is a small molecule.
- Current patent strength is low, with no broad blocking right expected to prevent generic substitution.
- ViiV and GSK do not generally disclose a current standalone Epivir revenue figure.
- Financial performance has followed the standard mature-drug pattern: high historical value, post-expiry price erosion, and residual low-growth revenue.
- The strongest remaining commercial factors are supply reliability, pediatric formulations, procurement access, and legacy clinical use.
- Newer regimens such as Dovato, Triumeq, Biktarvy, and other integrase inhibitor combinations limit standalone Epivir growth.
- Epivir should be assessed as a mature generic-exposed asset, not as an exclusivity-driven pharmaceutical growth product.
FAQs About Epivir Patents, Revenue, and Generic Competition
Is Epivir still a protected drug?
No. The principal lamivudine patent rights that supported Epivir's original exclusivity have expired, and generic lamivudine is widely available.
Is Epivir the same as lamivudine?
Epivir is a brand of lamivudine. Generic lamivudine contains the same active ingredient, subject to FDA approval, quality, bioequivalence, and labeling requirements.
Does Epivir-HBV have separate patent protection from Epivir?
The hepatitis B product had separate regulatory positioning and labeling, but its use of lamivudine did not create a durable, independent composition-of-matter patent barrier after the underlying lamivudine patents expired.
Can a generic company launch lamivudine without a Paragraph IV challenge today?
Yes, where no unexpired blocking patent applies to the relevant product and indication. A generic applicant can rely on the applicable abbreviated approval pathway without challenging an expired patent.
Is Epivir still commercially important to ViiV Healthcare?
Epivir remains part of ViiV's legacy HIV portfolio, but it is not comparable in commercial importance to newer branded HIV products and complete regimens. Its current value is primarily residual and portfolio-based.
References
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Food and Drug Administration. (2023). Epivir (lamivudine) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023). Epivir-HBV (lamivudine) prescribing information. U.S. Department of Health and Human Services.
-
GlaxoSmithKline. (2009). GlaxoSmithKline and Pfizer complete transaction to create ViiV Healthcare. https://www.gsk.com
-
National Library of Medicine. (2024). DailyMed: Lamivudine and Epivir labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov
-
U.S. Patent and Trademark Office. (1989). U.S. Patent No. 5,047,407: Nucleoside analogues. U.S. Department of Commerce.
-
ViiV Healthcare. (n.d.). About ViiV Healthcare and HIV medicines. https://viivhealthcare.com
